Skip to main content
SpringerLink
Log in

Il ruolo della cabergolina nella patologia ipofisaria. Efficacia e tossicità

  • Rassegna
  • Published:
L'Endocrinologo Aims and scope

Sommario

La cabergolina è oggi ampiamente utilizzata nel trattamento di diverse malattie di origine ipofisaria, essendo dotata di un ottimo profilo di tollerabilità. Nel trattamento dei disturbi iperprolattinemici detiene il ruolo di terapia di prima linea con ottimi risultati nel controllo dei livelli ormonali, delle lesioni espansive sottostanti e dei sintomi ad essi correlati. Recenti lavori ne hanno anche sottolineato l’efficacia nel trattamento dell’acromegalia e della malattia di Cushing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Bibliografia

  1. Hofland LJ, Feelders RA, de Herder WW, Lamberts SW (2010) Pituitary tumors: the sst/D2 receptors are molecular targets. Mol Cell Endocrinol 326:89–98

    Article  CAS  PubMed  Google Scholar 

  2. Ciccarelli E, Miola C, Grottoli S et al. (1993) Long term therapy of patients with prolactinoma using repeatable injectable bromocriptine. J Endocrinol Metab 76:484–488

    CAS  Google Scholar 

  3. Wang AT, Mullan RJ, Lane MA et al. (2012) Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev 1:33

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Melmed S, Casanueva FF, Hoffman AR et al. (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guidelines. J Clin Endocrinol Metab 96:273–288

    Article  CAS  PubMed  Google Scholar 

  5. Dekkers OM, Lagro J, Burman P et al. (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonist: systematic review and meta-analysis. J Clin Endocrinol Metab 95:43–51

    Article  CAS  PubMed  Google Scholar 

  6. Barber TM, KenKre J, Garnett C et al. (2011) Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma. Clin Endocrinol (Oxf) 75:819–824

    Article  CAS  Google Scholar 

  7. Ferone D, de Herder WW, Pivonello R et al. (2008) Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab 93:1412–1417

    Article  CAS  PubMed  Google Scholar 

  8. Sandret L, Maison P, Chanson P (2011) Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96:1327–1335

    Article  CAS  PubMed  Google Scholar 

  9. Bernabeu I, Alvarez-Escolá C, Paniagua AE et al. (2013) Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary 16:101–108

    Article  CAS  PubMed  Google Scholar 

  10. Pivonello R, De Martino MC, Cappabianca P et al. (2009) The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94:223–230

    Article  CAS  PubMed  Google Scholar 

  11. Feelders RA, de Bruin C, Pereira AM et al. (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N Engl J Med 362:1846–1848

    Article  CAS  PubMed  Google Scholar 

  12. Drake WM, Stiles CE, Howlett TA et al. for the UK Dopamine Agonist Valvulopathy Group (2014) A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab 99:90–96

    Article  CAS  PubMed  Google Scholar 

Download references

Conflitto di interesse

Gli autori Alessandro Berton e Silvia Grottoli dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Author information

Authors and Affiliations

  1. SCDU Endocrinologia, Diabetologia e Metabolismo, AO Città della Salute e della Scienza di Torino, Università degli Studi di Torino, C.so Dogliotti 14, 10126, Torino, Italia

    Alessandro Berton & Silvia Grottoli

Authors
  1. Alessandro Berton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silvia Grottoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvia Grottoli.

Additional information

Proposta da R. Cozzi.

Materiale elettronico supplementare

I link al materiale elettronico supplementare sono elencati qui sotto.

Scheda di autovalutazione (DOC 27 kB)

RISPOSTE (DOC 25 kB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Berton, A., Grottoli, S. Il ruolo della cabergolina nella patologia ipofisaria. Efficacia e tossicità. L'Endocrinologo 15, 213–217 (2014). https://doi.org/10.1007/s40619-014-0065-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-014-0065-2

Parole chiave

Search

Navigation